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Abstract Animal models are indispensible tools for
advancing understanding of the cause of any given
disease and developing new treatments. Developing
animal models for schizophrenia presents formidable
challenges owing to the distinctively human nature of
the symptoms that define it and the thus-far-obscured
underlying biological mechanisms. Nevertheless, prog-
ress has been and continues to be made in this important
field of endeavor. This article discusses the challenges
facing investigators who seek to develop and use animal
models for translational research in schizophrenia and the
responses that have emerged to those challenges, as well
as the likely pathways that will lead to future progress.
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Introduction
Animal models are indispensable tools in the service of
modern medicine. The conceptual paradigm of disease in
modern medicine is based on a causal assumption that can
be illustrated as follows:
Etiology ! Biologicalmechanism ! Signs=Symptoms
An etiology is an inducing condition that may be
transitory in nature and temporally remote from the clinical
manifestation of the disease (eg, prenatal exposure),
whereas the mechanism refers to the consequent underlying
biological perturbations that are contemporaneous with the
signs and symptoms. Although it is represented in the
schematic above as a unitary process, biological mechanism
may be more accurately considered to be a manifold
process that includes several subcomponents. Similarly,
the defining signs and symptoms of disease are often
manifold (eg, syndromatic).
The principle underlying the use of animal models to
expand medical knowledge is that an animal model is a
tool investigators can use to leverage what is known
about a disease to discover unknown aspects of the
disease. Therefore, the anchor that connects the animal to
the human disease is always what is already known
about the latter. This disease-oriented use of animal
models is distinct from the “toxicologic” use of animal
models in medical research, in which a putative toxin is
administered, and pathological changes are screened
broadly.
Basedonthedisease-orientedapproach,animalmodelscan
aid discovery in medicine in three broad ways: 1) discovering
the etiologyofa specificdisease,2)discoveringthe biological
mechanism underlying a specific disease, and 3) identifying
and/or evaluating new treatments (eg, drugs) or treatment
targets (eg, receptors).
As discussed in the subsequent sections of this article,
investigators intending to exploit this paradigm in the
service of advancing knowledge about schizophrenia face a
formidable, although not insurmountable challenge because
little other than the symptoms of this disease has been
firmly established, and there are major barriers to modeling
those symptoms. As a result, investigators have turned to
alternate approaches, including substituting endophenotypes
for symptoms and putative mechanisms for established
mechanisms.
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When an animal exhibits a phenotypic feature that
resembles a phenotypic feature of a medical disease, the
model is said to have face validity for that disease, at least
with respect to that specific phenotype. The stronger the
fidelity that exists between the human and animal pheno-
type, the stronger the face validity. As psychiatric diseases
such as schizophrenia are essentially defined by their
characteristic symptoms, most notably those delineated in
the DSM-IV [1], intuitively, the most valuable type of face
validity an animal model could exhibit would be face
validity for these disease-defining symptoms. As discussed
subsequently, face validity can be established for pheno-
types other than the characteristic symptoms, but this
strategy poses risks.
The DSM-IV describes five core features of schizophrenia
[1]. The first four—delusions, hallucinations, disorganized
speech, and disorganized or catatonic behavior—are catego-
rized as “positive” symptoms. The final feature is negative
symptoms, which the DSM-IV indicates include affective
flattening, alogia (poverty of speech), and avolition (poverty
of volitional behavior). It becomes immediately apparent
from the list of core features that developing animal models
with good face validity for the defining symptoms of
schizophrenia is highly problematic. Hallucinations and
delusions are subjective phenomena, and without language
or a reliable and readily measurable neurobiological marker
for these internal phenomena, it is not possible to identify
with certitude when an animal may be experiencing these
states or even something analogous. It goes without saying
that the symptom of disorganized speech cannot be modeled
in infrahumans, owing to the unique status of human
language and our limited ability to decipher vocal commu-
nications among animals. The fourth positive symptom
described in the DSM-IV, disorganized or catatonic behavior,
can in principle be modeled in animals; however, on its own,
this is feature is not highly schizophrenia specific. One can
easily envision an animal such as a rodent exhibiting, for
example, grossly disorganized behavior as a result of a host
of neural or neuromuscular perturbations that have little
relevance to the higher order thought process disturbance
that characterizes schizophrenia.
With regard to negative symptoms, only avolition is
potentially modelable in animals (eg, by animals who display
decreased motivation for normal social interactions). Indeed,
social behavioral deficits induced by the administration of
phencyclidine, an N-methyl-D-aspartate receptor antagonist,
have been proposed as face valid models of negative
symptoms [2]. However, avolition and the other negative
symptoms are also seen in depression and therefore are not
specific to schizophrenia. Thus, it would be difficult to
assign strong validity for schizophrenia to an animal model
that only exhibited negative features without some other co-
expressed features that might link it more specifically to
schizophrenia. On the whole, the ability to model the
characteristic and defining features of schizophrenia is
severely hampered because these features are not modelable
in animals in any practical manner currently known, or they
are potentially modelable but are, by themselves, not specific
to schizophrenia.
It should be noted that some controversy exists regarding
the importance of face validity, particularly face validity for
the defining symptoms of schizophrenia, with some arguing
that it is of primary importance [3], and others that it is the
least important type of validity and perhaps not important at
all [4]. We tend to the former opinion. As stated previously,
the starting point in developing useful animal models for a
medical disease is what is firmly known about the disease.
Face validity for a disease may decline in importance when
there exists a fairly firm understanding of the underlying
etiology or mechanism. In that case, the characteristic
symptoms of the disease can be confidently replaced by the
well-established mechanistic processes as the anchor for
development of animal models. For example, if elevated
mesolimbic dopamine transmission was firmly established
to be the underlying cause of positive symptoms in
schizophrenia patients, then rats with elevated mesolimbic
dopamine would be a strongly valid model of the disease,
even if this produced behaviors in the rats (eg, excessive
locomotor activity) that are not homologous to positive
symptoms in schizophrenia patients.
However, until such a level of understanding regarding
the underlying causes of schizophrenia is achieved, the
clinical features of schizophrenia are arguably the only
things that are currently firmly known about the disease
(vide infra). For all intents and purposes then, they are
equivalent to its definition. As such, the inherent difficulties
establishing face validity are a very significant challenge to
the enterprise of developing useful animal models of this
disease, but as seen subsequently, alternate strategies have
been adopted, namely modeling nonsymptom phenotypes,
or endophenotypes. These strategies offer greater potential
opportunities to establish animal models with face validity,
albeit for these nonsymptom phenotypes.
Modeling Underlying Causes of Schizophrenia
An animal model that replicates the established etiology or
mechanism underlying a disease is commonly described as
having etiologic validity [4, 5￿￿]. Although the term
mechanistic validity is not in use, we believe such a term
should be adopted, as it would be useful to distinguish an
animal that modeled the inducing conditions of the disease
(etiologic validity), which may be temporally remote and
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utero toxin exposure), from an animal that modeled the
mechanism that is contemporaneous with the clinical
features and is believed to sustain their expression. Thus,
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
animal model of Parkinson’s disease could be considered
to have mechanistic validity for Parkinson’s disease due
to the damage to the substantia nigra in Parkinson’s
disease sufferers and MPTP-treated animals. However,
this model clearly does not have etiologic validity
because MPTP is not the cause of idiopathic Parkinson’s
disease [6].
Notwithstanding an abundance of theories and putative
candidates, neither the etiology nor the biological mechanism
of schizophrenia is known with any certitude, except that
the mechanism ultimately involves a disturbance in
central nervous system function [7￿, 8￿￿]. All mechanisms
are speculative at present. Even the most well-developed
mechanistic construct, the dopamine hypothesis, is just
that—a hypothesis—as pathophysiologic evidence for
increased dopamine transmission in schizophrenia remains
sparse and inconclusive [9]. The strongest support for this
theory is circumstantial, the ability of dopamine-2 (D2)-
receptor antagonists to ameliorate some of the symptoms
[10] and the tendency of dopamine agonists such as
amphetamine to induce symptoms similar to positive
psychotic symptoms in nonschizophrenics. However,
drugs may produce amelioration or induction of disease
symptoms by altering biological systems that are not
themselvesdirectlyinvolvedinthedevelopmentofthedisease
butcanneverthelessmodulatethosesystems.Asaresultofthe
current state of understanding, it can be concluded that
etiologic (and mechanistic) validity for schizophrenia in an
animal model is not presently an achievable goal.
Employing Alternate Strategies
Because of the challenges to modeling in animals the
underlying causes and characteristic symptoms of schizo-
phrenia, researchers have sought out alternative strategies.
These strategies include modeling nonsymptom pheno-
types of schizophrenia that may be inherently more
modelable in animals and modeling putative mechanisms
and etiologies in lieu of established ones.
Modeling Endophenotypes as an Alternative to Symptoms
An endophenotype literally means an “inside” phenotype
and refers to phenotypes that are not visible by the
conventional examination used to observe or elicit the
characteristic signs or symptoms of a disease. Thus, unlike
grossly disorganized speech or bizarre delusions, which are
readily observed or elicited through a routine clinical
interview, endophenotypes are accessible only by specific
and specialized testing. Several desirable characteristics have
been established to help identify optimal schizophrenia
endophenotypes for study and modeling from among the
larger set of putative biomarkers for this disease [11￿, 12].
These include strong heritability and presence in nonaffected
relatives of schizophrenia patients at a higher rate than in the
general population. The two categories of schizophrenia
endophenotypes that have received the most attention with
respect to modeling in animals are neurophysiologic endo-
phenotypes and cognitive endophenotypes.
Several neurophysiologically based endophenotypes for
schizophrenia have been identified and shown to be highly
replicable, including reduced prepulse inhibition of the startle
reflex (PPI), reduced P50 auditory evoked potential suppres-
sion, and abnormal smooth eye pursuit. A comprehensive
discussion of these endophenotypes is beyond the scope of
this article but can be found elsewhere [13]. PPI and P50
suppression are considered operational measures of informa-
tion “gating,” a normal function of the central nervous
system whereby information is selectively filtered. Informa-
tion gating is believed to be perturbed in individuals with
schizophrenia, and some experts have proposed that this is of
fundamental causal importance to the symptomatic expres-
sion of the disease [14]. The major advantage of these gating
endophenotypes is that they can be successfully modeled in
animals, often with strong homology to the human version
and under similar parametric conditions [15]. Thus, estab-
lishing strong face validity for these endophenotypes is much
more achievable than it is for the disease-defining symptoms,
a n dm o s tc l a i m st h a ta na n i m a lm o d e lh a sf a c ev a l i d i t yf o r
schizophrenia are in fact more precisely referring to face
validity for one or more endophenotypes of the disease.
Another set of well-documented endophenotypes asso-
ciated with schizophrenia are deficits in certain domains of
cognitive functioning. Seven specific domains of cognitive
functioning have been identified as consistently deficient in
schizophrenia patients by the Measurement and Treatment
ResearchtoImproveCognitioninSchizophrenia(MATRICS)
committee, a National Institute of Mental Health-sponsored
initiative [16, 17]. These domains are working memory,
verbal memory, visual learning, attention/vigilance, abstract
reasoning, social cognition, and speed of processing.
MATRICS has also identified specific neuropsychological
tests that are best suited to assess each of these domains of
cognitive dysfunction [18].
There is a long history of assessing cognitive perfor-
mance in infrahuman species, including areas that are
analogous to most of the domains of human cognition that
are deficient in schizophrenia [19, 20]. Thus, modeling
cognitive deficits associated with schizophrenia in animals
is generally believed to be a very useful strategy, and
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animal tests and develop novel ones that have validity for
domains of cognitive performance identified by MATRICS
[21, 22]. Cognitive endophenotypes generally cannot be
modeled with the same degree of cross-species homology
that is possible for neurophysiologic endophenotypes such
as PPI and P50 suppression, in large part because many of
the human tests of cognition rely on verbal communication.
However, cognitive endophenotypes have an advantage in
that they are justifiably considered more than a biomarker
or surrogate phenotype for the defining symptoms of
schizophrenia; rather, they are generally considered to be
an unofficial (ie, not part of the DSM-IV criteria) third
clinical syndrome of the disease (together with the positive
and negative symptoms) and an important target for clinical
remediation in their own right. As such, cognitive
deficits often are not described as endophenotypes of
schizophrenia as much as clinical features of the disease.
Indeed, cognitive deficits have been shown to contribute
significantly to morbidity and disability independent of
positive and negative symptoms [23, 24]. Nevertheless,
we have included them as endophenotypes of schizophre-
nia in this article because they are not part of the official
DSM clinical definition of the disease and thus are not
factored into the diagnosis. Furthermore, they cannot be
assessed with the normal clinical examination used
routinely to determine the diagnosis of schizophrenia
(eg, observation, interview, history). Instead, they require
specialized and specific tests.
Although modeling endophenotypes of schizophrenia in
lieu of characteristic symptoms provides a promising and
viable alternative strategy to the bleak prospects of
modeling symptoms of the disease, the endophenotype
strategy is laden with pitfalls as well. In general, the
endophenotypes identified in schizophrenia and used to
develop animal models lack specificity for schizophrenia.
For example, PPI has been shown to be reduced in patients
with many neuropsychiatric and some non-neuropsychiatric
diseases [25￿]. Similarly, the cognitive deficits described
among schizophrenia patients are also present in many
brain-based diseases. This then raises the question of
exactly what disease is an animal with gating or cognitive
endophenotypes modeling?
Another related problem with relying on animal models
that have face validity for an endophenotype of schizophrenia
derives from our lack of understanding of the causal
relationship that most endophenotypes of schizophrenia have
tothepathologicalprocessesandsymptomsofthedisease.An
endophenotype may be associated with schizophrenia in
several ways, and it is possible that any given endophenotype
may have an epiphenomenal relationship to the causal
pathway linking etiology, mechanism, and symptoms of
schizophrenia. If an endophenotype is an epiphenomenon
and not directly and intrinsically connected through a causal
relationship to the disease mechanism, then information
gleaned from the study of that endophenotype in animals
may produce misleading knowledge. For example, it is
assumed that deficient PPI, as an indicator of dysfunc-
tional sensorimotor gating, is intrinsically connected to
the pathophysiologic changes in schizophrenia that give
rise to the clinical features of the disease. However, it
has been difficult to link abnormal PPI consistently with
any clinical manifestation of schizophrenia, such as
positive or negative symptoms or even cognitive deficits
[25￿]. Sometimes even endophenotypes with apparently
compelling causal connections to the clinical manifesta-
tion can present potential pitfalls for investigators if the
causal links are not firmly established. For example,
amyloid-containing brain plaques are the most salient
pathophysiologic finding in Alzheimer’sd i s e a s e .T h e
plaques represent an obvious endophenotype to model in
animals, and this strategy has been widely used by
Alzheimer investigators. However, autopsy studies have
revealed that some people with significant amyloid plaque
build-up do not develop Alzheimer’s disease. Thus far,
studies have not consistently shown that reducing these
plaques leads to cognitive improvement in patients with
Alzheimer’sd i s e a s e[ 26].
Modeling Etiologic and Mechanistic Constructs
As previously stated, neither the etiology nor biological
mechanism underlying schizophrenia is known; thus,
establishing strong etiologic or mechanistic validity is not
currently possible. Animal models that incorporate a
mechanistic or etiological construct of schizophrenia are
deemed to have construct validity, a term often used
interchangeably with etiologic validity but what in fact is
a distinct type of validity. The term construct validity
connotes a theoretical aspect and reflects the speculative
nature of the mechanisms modeled. In some cases, a single
modeled feature can represent both face and construct
validity, but it is important to recognize that the two types
of validity are not necessarily linked. For example, a rat
strain that has naturally reduced PPI exhibits construct
validity regarding the sensorimotor gating deficits that are
theorized to be linked to the neural disturbance and the
clinical manifestation of schizophrenia (the disrupted
sensorimotor construct of schizophrenia). It also exhibits
face validity for PPI disruption, as the PPI abnormality in
these rats is homologous to the PPI abnormality in
schizophrenia patients and is elicited and measured using
identical parametric conditions. On the other hand,
amphetamine-induced hyperlocomotion, the basis of many
animal models of schizophrenia, may exhibit construct
validity for the excessive dopamine theory of schizophre-
330 Curr Psychiatry Rep (2010) 12:327–334nia, but not face validity, because increased locomotor
activity is not an established characteristic feature of
schizophrenia [27].
Enhancing Disease Relevance: Multiple Traits,
Predictive Validity, and Temporal Validity
The potential pitfalls posed by the need to model
endophenotypes and etiologic/mechanistic constructs of
schizophrenia can be mitigated in certain ways. One way
is to develop animal models with multiple endophenotypes
and mechanistic constructs associated with schizophrenia.
Although any single schizophrenia endophenotype may
lack specificity for schizophrenia, the coexistence of several
such endophenotypes in a single model increases the likely
relevance of the model for schizophrenia. Therefore, an
animal model that exhibits decreased PPI and P50
suppression and poor performance on tests of vigilance
and working memory will engender more confidence in its
validity for schizophrenia than an animal model that only
exhibits one of these features.
The extent to which an animal model responds to
manipulations in a way that is consistent with the human
disease it is modeling determines the extent to which it
exhibits predictive validity. For animal models of schizo-
phrenia, predictive validity most commonly refers to the
animal model’s ability to respond selectively to antipsy-
chotic drugs [4, 5￿￿]. The establishment of predictive
validity for an animal model is very important for the
purpose of establishing it as a useful tool to discover new
treatments [4, 5￿￿]. However, like multiple-modeled traits,
establishing strong predictive validity can also generally
mitigate the inherent weaknesses of having to rely on
modeled endophenotypes and/or mechanistic constructs
whose causal connection to the core mechanisms and
symptoms of schizophrenia are speculative. Thus, in an
animal model exhibiting PPI deficits, demonstration that
the PPI deficits are selectively ameliorated by antipsy-
chotics, but not non-antipsychotic psychotropics, enhances
the overall validity of the model. All currently established
antipsychotics share the ability to antagonize transmission
through D2-receptors. Therefore, there is a risk that an
animal model with apparent predictive validity may be
functioning as nothing more than an in vivo assay for D2-
receptor affinity. For this reason, it is important to develop
animal models that reflect known aspects of antipsychotic
efficacy that transcend simple dopamine receptor affinity.
Clozapine has relatively weak D2 binding affinity among
established antipsychotics but is recognized as the most
efficacious antipsychotic [28]. Furthermore, antipsychotic
efficacy in schizophrenia patients is understood to begin
with the first dose ingested and to grow in strength with
repeated doses until it reaches a plateau after several weeks
of daily use [29]. Thus, predictive validity in an animal
model of schizophrenia can be strengthened beyond
demonstrating simple responsiveness to acute antipsychotic
administration if it 1) exhibits a response that is at least as
strong (and preferably stronger) to clozapine as it is to more
potent and selective D2 antagonists such as haloperidol and
2) exhibits a stronger response to repeated administration
over time than it does to acute administration.
Evidence strongly implicates a genetic contribution to
schizophrenia and subtle prodromal abnormalities before
the full emergence of symptoms, which occurs in most
cases 5 to 10 years after puberty. This distinct temporal
feature of latency between inducing conditions and full
manifestation of the disease affords another opportunity to
strengthen the validity of an animal modeling for schizo-
phrenia if this feature can be modeled [30].
A comprehensive review of animal models with potential
relevance to schizophrenia is beyond the scope of this article,
but in Table 1, we present a comparison of four rodent
models that represent different inducing strategies: environ-
mental, pharmacologic, neuroanatomic, and genetic.
Future Directions
Despite the prodigious challenges facing investigators in
their efforts to develop better schizophrenia-relevant animal
models, there is good reason to be optimistic that progress
will continue to be made in developing animal models with
stronger validity and utility. Sources of such advancements
are most likely to derive from findings emanating from the
study of schizophrenia patients themselves, which will lead
to advances in developing animal models through the
process of back translation. For example, identification of
additional endophenotypes or certain aspects of currently
known endophenotypes that have greater specificity for
schizophrenia will provide new targets to model in animals
that have stronger relevance to schizophrenia. Identification
of efficacious drugs with novel mechanisms that do not rely
on D2-receptor antagonism could also provide new tools to
evaluate the predictive validity of animal models and
thereby differentiate those that have specific predictive
validity for schizophrenia from those whose apparent
validity was spurious.
Conclusions
With no definitive knowledge of the mechanisms underly-
ing schizophrenia and no realistic prospect of modeling its
characteristic symptoms, the effort to model schizophrenia
in infrahumans might appear futile. However, alternate
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332 Curr Psychiatry Rep (2010) 12:327–334strategies are available that salvage this endeavor. These
strategies include modeling endophenotypes of schizophre-
nia as a surrogate for disease-defining symptoms and
modeling putative mechanisms and etiologies (mechanistic
and etiologic constructs) in lieu of established ones. To the
extent that these alternate strategies rely on unsubstantiated
causal assumptions about these endophenotypes and con-
structs, they introduce risks of attributing validity to animal
models with low relevance to essential features of schizo-
phrenia. However, these risks can be mitigated by devel-
oping animal models that incorporate multiple
endophenotypic and/or construct similarities rather than
just a single one, thereby increasing the likelihood of their
relevance to schizophrenia. In addition, demonstration of
predictive validity can buttress confidence in the validity of
animal models that rely on mechanistic or etiologic
constructs and endophenotypes. This is particularly relevant
if the predictive validity incorporates established nuanced
features of antipsychotic drug efficacy, such as the
differential efficacies and the therapeutic time course seen
in schizophrenia patients. Back translation of future find-
ings about schizophrenia from patients who suffer from it
will provide opportunities to develop animal models with
stronger validity and usefulness.
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